About Us
R&D
Pipeline
News
Partnering
Careers
Contact
中
中
Home
About Us
Company Overview
R&D Leader
R&D Team
Board of Directors
Partners
R&D
R&D Strategy
Medical Information
Pipeline
TGRX-678 BCR-ABL inhibitor
TGRX-326 ALK/ROS1 inhibitor
TGRX-814 BCL2 inhibitor
News
Partnering
Careers
Opportunities
Company Culture
Contact
Contact Us
Message
Achieve precision medicine with disruptive strategies
We focus on developing the next generation of targeted anticancer drugs by designing the novel structure of small molecules.
Our Science
Achieve precision medicine with disruptive strategies
We focus on developing the next generation of targeted anticancer drugs by designing the novel structure of small molecules.
Our Science
Mission drives innovation, and innovation improves quality of life
We bring solutions to cancer drug resistance from our deeply integrated strength in chemistry, biology and medicine.
About Us
The next generation of cancer therapies that meet urgent clinical needs
We are building a pipeline of targeted cancer therapies by harnessing our artificial intelligence platform and expertise of structure-based design.
Our Pipeline
TargetRx Signs Collaboration Agreement With Simcere Zaiming
TargetRx and Simcere Zaiming Enter Collaboration Agreement for Third-Generation ALK inhibitor TGRX-326.
News
Collaboration and Creation
Looking forward to working with you to explore innovative technologies and conduct research and development of products.
Collaboration
Fighting cancer is our mission, make it yours
Join world-class innovative and dynamic team who are dedicated to bringing differentiated therapies to patients.
Join Us
Fighting cancer is our mission, make it yours
Join world-class innovative and dynamic team who are dedicated to bringing differentiated therapies to patients.
Join Us